Saidikang Medical Completes Over RMB 100 Million Series B Financing Co-led by Longpan Investment and Shanghai State-owned Assets Capital

Saidikang Medical Technology (hereinafter referred to as “Saidikang”), a global tissue engineering and regenerative medicine company, recentlyAnnounces Completion of Over RMB 100 Million in Series B Financing, Co-Led by LapamCapital and Shanghai Healthcare Capital (SHC). This financing will be used to accelerate the global commercial expansion of Saide Dikang's core products, particularly in the Chinese and U.S. markets, as well as to speed up the research and development and clinical studies of new products.

PermeaDerm Biosynthetic Membrane Repair Material

Since its establishment in 2019, Saidikang has built a proprietary global technology platform for biosynthetic membrane repair materials. With R&D centers and production bases in both China and the United States, the company’s core product has become the first and only innovative repair solution for acute and chronic wounds in this field to receive U.S. FDA approval and be covered by U.S. medical insurance.

Ms. Sun Lin, Founder of SideDiConstated, “The completion of our Series B financing marks a significant milestone in the development of CytoMed. We are deeply grateful to SHC and LapamCapital for their recognition and support. Through the team’s relentless efforts over the past few years, the company has made positive progress in independent innovation, clinical development in both China and the United States, and global commercial layout. This round of financing will fuel our continued innovation in tissue engineering and regenerative medicine, accelerate the clinical translation of our products and expansion into global markets, and attract top-tier talent to join our team. Together, we are committed to providing high-quality, full-cycle clinical solutions for more patients.”

Differentiation and Migration of Fibroblasts on 3D Microscaffolds

Yu Zhihua, Chairman of Lapam Capitalstated, “Saidikon’s technological innovations and clinical translation capabilities in the fields of tissue engineering and regenerative medicine are remarkable. Its products have upgraded traditional wound repair therapies, achieving international leadership and providing hundreds of millions of patients with acute and chronic wounds with more efficient and higher-quality treatment options. LapamCapital is pleased to participate in the company’s future development through investment, leveraging its resources and experience to help the founding team drive the enterprise’s long-term growth. We look forward to seeing more innovative products translated into clinical applications, bringing benefits to patients worldwide.”

Bioactive Coatings Interact with Fibroblasts to Generate Superior Adhesion

Guo Qiushan, Partner at SHCIt stated: “Saide Dikang possesses a globally leading biosynthetic membrane material technology platform and has established R&D centers in both China and the United States. Its core product, PermeaDerm®, is an ultra-thin, elastic, biocompatible, transparent, and flexible reparative material. Its excellent conformability and adhesiveness enable patients to return to normal life earlier. The entire treatment process is visible without the need for dressing changes; the material detaches automatically after wound healing, effectively avoiding secondary injury caused by removal. It also demonstrates prominent clinical advantages in reducing infection risks and minimizing scar formation. The product has been approved for the treatment of patients with acute and chronic wounds in the United States, Singapore, Malaysia, and Macau, China. This investment will help Saide Dikang achieve greater breakthroughs in technological innovation, indication expansion, and global commercialization, propelling the company to become a benchmark enterprise in the field of global regenerative medicine.”

Since its inception, Saide Dikang has remained steadfast in its mission to “bring disruptive innovation to healthcare,” leveraging advanced tissue engineering repair technologies to promote the broader clinical application of biosynthetic tissue engineering techniques, fill market gaps for tissue engineering scaffold materials both domestically and internationally, and benefit patients worldwide.